Compare Abbott Laboratories (ABT) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Carparts.Com Inc — how do they compare? Abbott Laboratories trades at $109.56 (market cap $187.95B), while Carparts.Com Inc trades at $6.41 (market cap $51.67M). The key difference: Abbott Laboratories is far larger — about 3637.5× Carparts.Com Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.
| ABT | PRTS | |
|---|---|---|
Market Cap | $187.95B | $51.67M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $11.40 |
52-Week Low | $82.57 | $3.88 |
Enterprise Value | $214.96B | $66.64M |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
CarParts.com (PRTS) trades at $6.32, down 6.37% today, with a bullish technical signal despite negative profitability metrics. The company has beaten earnings expectations for three consecutive quarters, though revenue has declined from $676M in 2023 to $548M in 2025. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25M credit facility, while analyst consensus remains positive with 60% buy ratings.
The outlook is mixed: technical indicators and analyst sentiment suggest potential upside, but fundamental challenges persist with negative net income margins and cash flow concerns. Key risks include ongoing operational losses and competitive pressures in the auto parts e-commerce space, requiring careful monitoring of the company's turnaround execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
